CorMedix Inc (CRMD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $370.64M
Last updated: Nov 17, 2026 at 11:05 AM ET
CorMedix Inc (CRMD) Financials: Revenue, Profit and Cash Flow
CorMedix reported revenue of $297.84M for the fiscal year ended Dec 31, 2025, up 585.1% from the year before. That year, net income was $163.06M with a net margin of 54.7%, operating cash flow was $175.05M and free cash flow was $172.79M. The quarter ended Sep 30, 2026 had revenue of $54.52M and net income of -$14.72M.
Revenue and Margins
The operating margin was 50.4% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $224.10K, a compound annual rate of 122.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $297.84M | +585.1% | 92.6% | 50.4% | 54.7% |
| Dec 2024 | $43.47M | N/A | 92.7% | -51.4% | -41.2% |
| Dec 2023 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2022 | $65.41K | -65.7% | 94.3% | -46819.9% | -45409.9% |
| Dec 2021 | $190.94K | -20.2% | 22.0% | -15417.5% | -14774.7% |
| Dec 2020 | $239.23K | -15.5% | 14.4% | -11378.4% | -9207.7% |
| Dec 2019 | $283.27K | -34.1% | -31.8% | -7416.3% | -5801.3% |
| Dec 2018 | $429.80K | +30.5% | 7.7% | -6250.4% | -6242.4% |
| Dec 2017 | $329.33K | +47.0% | 65.1% | -9997.4% | -10023.4% |
| Dec 2016 | $224.10K | N/A | -63.6% | -11048.8% | -10996.5% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $297.84M | $43.47M | $0 | $65.41K | $190.94K | $239.23K | $283.27K | $429.80K | $329.33K | $224.10K |
| Cost of revenue | $22.09M | $3.03M | $0 | $3.73K | $148.94K | $204.85K | $373.23K | $396.79K | $114.96K | $366.67K |
| Gross profit | $275.75M | $40.28M | $0 | $61.67K | $42.00K | $34.38K | -$89.97K | $33.01K | $214.36K | -$142.57K |
| Research and development | $19.33M | $3.94M | $13.16M | $10.68M | $13.13M | $13.38M | $11.05M | $18.82M | $24.49M | $15.74M |
| Operating income | $150.14M | -$22.36M | -$48.96M | -$30.62M | -$29.44M | -$27.22M | -$21.01M | -$26.86M | -$32.92M | -$24.76M |
| Net income | $163.06M | -$17.93M | -$46.34M | -$29.70M | -$28.21M | -$22.03M | -$16.43M | -$26.83M | -$33.01M | -$24.64M |
| EBITDA | $164.34M | -$21.41M | -$48.78M | -$30.38M | -$29.28M | -$27.03M | -$20.64M | -$26.79M | N/A | -$24.74M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.52M | $101.93M | $127.43M | $118.37M | $104.28M | $39.74M | $39.08M | $31.21M | $11.46M | $806.12K | $0 | $304.11K |
| Gross profit | $30.00M | $77.13M | $105.12M | $107.31M | $93.08M | $37.87M | $37.48M | $30.03M | $10.77M | $296.28K | -$818.54K | -$53.51K |
| Operating income | -$6.62M | $42.91M | $63.66M | $59.13M | $51.35M | $19.54M | $20.13M | $12.94M | -$3.29M | -$15.30M | -$16.70M | -$15.67M |
| Net income | -$14.72M | $25.99M | $38.60M | $14.02M | $108.56M | $19.83M | $20.64M | $13.46M | -$2.78M | -$14.15M | -$14.47M | -$14.75M |
Balance Sheet
As of Dec 2025, total debt of $146.07M exceeded cash and equivalents by $1.24M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $826.14M | $118.85M | $82.06M | $62.04M | $68.95M | $49.31M | $29.48M | $18.83M | $13.45M | $21.91M |
| Current assets | $367.05M | $114.58M | $79.45M | $59.55M | $66.47M | $48.18M | $29.35M | $18.67M | $13.27M | $21.83M |
| Cash and equivalents | $144.84M | $40.65M | $43.64M | $43.15M | $53.32M | $41.91M | $16.35M | $17.62M | $10.38M | $8.06M |
| Total liabilities | $420.83M | $34.19M | $11.92M | $6.98M | $6.15M | $5.09M | $5.83M | $13.89M | $6.26M | $4.09M |
| Short-term debt | $1.45M | $167.92K | $150.62K | $134.80K | $121.37K | $109.13K | $2.01K | N/A | N/A | $1.83K |
| Long-term debt | $144.63M | $0 | N/A | N/A | N/A | N/A | N/A | $6.13M | $0 | $0 |
| Shareholder equity | $405.31M | $84.66M | $70.14M | $55.06M | $62.80M | $44.22M | $23.65M | $4.93M | $7.19M | $17.81M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $917.75M | $904.05M | $815.64M | $826.14M | $750.86M | $252.60M | $149.58M | $118.85M | $77.59M | $57.73M | $68.02M | $82.06M |
| Total liabilities | $456.04M | $443.22M | $378.59M | $420.83M | $376.73M | $31.97M | $34.69M | $34.19M | $18.87M | $11.55M | $10.01M | $11.92M |
| Cash and equivalents | $355.15M | $256.69M | $178.09M | $145.82M | $48.49M | $159.31M | $66.29M | $40.65M | $35.29M | $28.54M | $35.18M | $43.64M |
| Shareholder equity | $461.71M | $460.83M | $437.05M | $405.31M | $374.13M | $220.63M | $114.89M | $84.66M | $58.71M | $46.18M | $58.01M | $70.14M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 98.7% of operating cash flow. Share repurchases came to 3.3% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $175.05M | -$50.62M | -$38.41M | -$24.36M | -$21.16M | -$21.97M | -$15.05M | -$23.70M | -$28.59M | -$22.27M |
| Capital expenditures | $2.26M | $116.00K | $327.30K | $219.36K | $1.43M | $112.64K | $36.57K | $48.89K | $151.99K | $58.72K |
| Free cash flow | $172.79M | -$50.73M | -$38.74M | -$24.58M | -$22.58M | -$22.08M | -$15.09M | -$23.75M | -$28.74M | -$22.32M |
| Share repurchases | $5.73M | $0 | N/A | N/A | N/A | N/A | $226.85K | N/A | N/A | N/A |
| Investing cash flow | -$308.43M | $21.23M | -$17.06M | -$3.71M | -$9.13M | $7.43M | -$12.02M | $1.56M | $10.36M | $11.42M |
| Financing cash flow | $238.45M | $26.32M | $55.92M | $17.90M | $41.76M | $40.10M | $25.80M | $29.40M | $20.52M | $7.09M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $89.70M | $86.24M | $42.38M | $94.46M | $30.86M | $29.99M | $19.74M | -$5.61M | -$13.65M | -$14.04M | -$17.31M | -$10.75M |
| Capital expenditures | $1.91M | $561.00K | $729.00K | $1.72M | $506.00K | $24.00K | $10.00K | $10.14K | $9.77K | $34.79K | $61.31K | $295.93K |
| Free cash flow | $87.79M | $85.68M | $41.65M | $92.74M | $30.35M | $29.97M | $19.73M | -$5.63M | -$13.66M | -$14.07M | -$17.37M | -$11.04M |
Frequently Asked Questions About CRMD
What is CorMedix's annual revenue?
CorMedix reported revenue of $297.84M for the fiscal year ended Dec 31, 2025.
How fast is CorMedix's revenue growing?
Revenue was up 585.1% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is CorMedix profitable?
Yes. CorMedix reported net income of $163.06M for the fiscal year ended Dec 31, 2025, with a net margin of 54.7%.
How much free cash flow does CRMD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $175.05M minus capital expenditures of $2.26M produced free cash flow of $172.79M.
How much debt does CorMedix have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $144.63M, short-term debt of $1.45M and cash and equivalents of $144.84M.
CRMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors